Targeting ABC transporters in PDAC – past, present, or future?
2024-07-10
(Press-News.org)
“[...] it is crucial for the future application of ABC transporter inhibitors [...] to develop a stratification protocol [...] to identify those PDAC patients who are most likely to benefit from chemosensitization induced by these inhibitors.”
BUFFALO, NY- July 10, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 20, 2024, entitled, “Targeting ABC transporters in PDAC – past, present, or future?”
In this new editorial, Cecilia Bergonzini, Elisa Giovannetti and Erik H.J. Danen from Leiden University discuss targeting ABC transporters in pancreatic ductal carcinoma (PDAC). Despite its lower incidence as compared to more common cancers such as lung or breast carcinomas, PDAC ranks as the third leading cause of cancer mortality in the US and the sixth worldwide. This is due to the fact that PDAC survival rates are among the lowest for cancer patients, around 13% in the US.
ATP-binding cassette (ABC) transporters represent a family of transmembrane proteins that, using the energy from ATP hydrolysis, extrude molecules from the cytoplasm to the exterior or into vesicles. Some of these transporters have been associated with resistance to a spectrum of structurally diverse chemotherapeutic drugs, earning them the name of multidrug resistance (MDR) pumps. One of the best-characterized ABC transporters is ABCB1 (MDR1). It is physiologically expressed in tissues such as kidney, liver, pancreas, intestine, the blood-brain barrier, and more, where it exerts a protective role, by extruding xenobiotics and potentially toxic molecules. Moreover, increased ABCB1 expression in tumors has been associated with poor prognosis.
“Paclitaxel is a bona fide substrate for ABCB1 [18] and ABCB1 has been implicated in paclitaxel and nab-paclitaxel resistance in multiple types of cancer [19, 20]. Could ABCB1 represent a therapeutic target in PDAC patients to suppress resistance against GnP? We have recently reported that ABCB1 can indeed play a critical role in paclitaxel resistance in PDAC cells [21].”
Continue reading: DOI: https://doi.org/10.18632/oncotarget.28597
Correspondence to: Erik H.J. Danen
Email: e.danen@lacdr.leidenuniv.nl
Keywords: PDAC; chemoresistance; ABCB1
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X, formerly Twitter
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Reddit
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
Oncotarget Journal Office
6666 East Quaker Street., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)
###
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-07-10
Machine learning models could enable earlier identification of at-risk children, aiding social workers and potentially improving outcomes, per Danish study of more than 100,000 children
###
Article URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0305974
Article Title: Predictive risk modeling for child maltreatment detection and enhanced decision-making: Evidence from Danish administrative data
Author Countries: Denmark, France
Funding: Funding for this project was ...
2024-07-10
Christmas or Ramadan might seem to come around more quickly each year, for people who pay more attention to time, are more forgetful of plans, and love a good holiday. A research team led by Ruth Ogden of Liverpool John Moores University, UK, and Saad Sabet Alatrany of Imam Ja'afar Al-Sadiq University, Iraq, published these findings in the open-access journal PLOS ONE on July 10, 2024. They suggest this could mean that someone’s experience of time is shaped not only by what they’ve done, but what is left to do.
“Christmas seems to come quicker each year,” is a staple of small talk. But the ...
2024-07-10
Perceived warmth and competence predict the influence of race, gender and age on callback decisions, suggesting social perceptions might underlie such hiring bias. The meta-analysis of North American correspondence studies is published July 10, 2024 in the open-access journal PLOS ONE by Carina Hausladen from the California Institute of Technology and ETH Zürich, Marcos Gallo from the California Institute of Technology, and colleagues.
In the labor market, applicants from marginalized groups continue to face disparate treatment. To ...
2024-07-10
A study led by the Hospital del Mar Research Institute, with Cima University of Navarra and Pompeu Fabra University, has identified a group of small molecules exclusive to liver tumors that could be key to developing cancer vaccines. These are microproteins, very small proteins expressed only by tumor cells. This can result in the activation of immune cells against the tumor. The study is published in Science Advances.
By integrating data from tumors and healthy tissue from over one hundred liver cancer ...
2024-07-10
NEW YORK and LOS ANGELES — In preclinical studies, a team of researchers from Mount Sinai Health System in New York City and City of Hope in Los Angeles report new findings on a therapeutic combination that regenerated human insulin-producing beta cells, providing a possible new treatment for diabetes. The findings were published today in Science Translational Medicine.
This work, led by Andrew F. Stewart, MD, Irene and Dr. Arthur M. Fishberg Professor of Medicine and Director of the Mount Sinai Diabetes, Obesity ...
2024-07-10
LOS ANGELES and NEW YORK — In preclinical studies, a team of researchers from City of Hope® in Los Angeles and Mount Sinai Health System in New York reports new findings on a therapeutic combination that regenerated human insulin-producing beta cells, providing a possible new treatment for diabetes. The findings were published today in Science Translational Medicine.
This work, led by Andrew F. Stewart, M.D., Irene and Dr. Arthur M. Fishberg Professor of Medicine and Director of the Mount Sinai Diabetes, Obesity and Metabolism Institute, began at the Icahn School of Medicine at Mount Sinai in 2015. The studies were a team effort. Adolfo ...
2024-07-10
Using genetic engineering techniques, investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center, the Lustgarten Laboratory and Bloomberg~Kimmel Institute for Cancer Immunotherapy have designed a novel type of cell to recognize and fight cancer.
To produce the cells, called Co-STAR (Co-stimulatory Synthetic T-cell receptor and Antigen Receptor) cells, the researchers combined genetic components of four types of cells that the body normally uses to defend against invaders to make ...
2024-07-10
The study also looked at safety of the AAV-mediated genome editing approach and found it had a good safety profile that includes little off-target effect and no detectable long-term integration of the AAV vector in the genome. “Our research suggested minimal potential risk and supports the feasibility of future clinical applications in humans,” said Wenliang Zhu, PhD, and physician-scientist Wan Du, MD, PhD, members of Chen’s lab at Mass Eye and Ear and first authors on the paper.
The study, led by Zheng-Yi Chen, DPhil, an associate scientist in the Eaton-Peabody Laboratories at Mass Eye and Ear (a member of the ...
2024-07-10
HOUSTON – (July 10, 2024) – The Controlled Release Society (CRS), the premier international, multidisciplinary society dedicated to the science and technology of drug delivery, has elected Rice University bioengineer Omid Veiseh to its College of Fellows.
The recognition is a prestigious acknowledgement of “outstanding and sustained contributions in the field of delivery science and technology,” according to the organization website.
“I am deeply honored to be elected to the CRS College ...
2024-07-10
More than 70 high school students and science teachers gathered at Young Middle School in Arlington this summer to learn about quantum information science (QIS). The annual workshop and camp are part of a national pilot program called Quantum for All led by Karen Jo Matsler, assistant professor in practice and master teacher in the UTeach program at The University of Texas at Arlington.
“Just the word ‘quantum’ scares people, which is why many teachers and school administrators ...
LAST 30 PRESS RELEASES:
[Press-News.org] Targeting ABC transporters in PDAC – past, present, or future?
